AltSonflex1-2-3

Phase 1Biologic

GSK

AltSonflex1-2-3 is one of 11 biologic programs targeting Shigellosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ShigellosisActive, not recruiting

ShigellosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Shigellosis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

—2

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 4

Bacteriophage

AAdaptive Phage Therapeutics, Inc.

Phase 2

1 5

MR-Vac

GSK

Phase 2

1 6

TYPHIBEV

GSK

Phase 2

1 7

Gsk's Investigational Vaccine 692342

GSK

Phase 1

—8

Ceftriaxon

IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group

Phase 2

1 9

AltSonflex1-2-3

GSK

Phase 1

1 10

Menacwy

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Immunogenicity

NCT07320716

Clinical

Trials by Indication[1]

Shigellosis1 trial

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

Completed· GSK logo

GSK·Phase 2·NCT06663436·200 enrolled

Immunogenicity1 trial

Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

Not yet recruiting· GSK logo

GSK·Phase 2·NCT07320716·528 enrolled

Diarrhoea1 trial

A Staged Phase I/II Observer-blind, Randomised, Controlled, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults in Europe (Stage 1) Followed by Age De-escalation From Adults to Children and Infants, and Dose-finding in Infants in Africa (Stage 2)

Completed· GSK logo

GSK·Preclinical·NCT05073003·551 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AltSonflex1-2-3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AltSonflex1-2-3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AltSonflex1-2-3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GSK

AltSonflex1-2-3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Shigellosis1 trial

Immunogenicity1 trial

Diarrhoea1 trial

References

Drug Info

Quick Facts

Related News